Oasmia
Oasmia Pharmaceutical is a Swedish speciality pharma company focusing on its proprietary XR-17 technology platform to develop novel formulations of well-established cytostatic oncology treatments for human and animal health. Key assets include Apealea (partnered with Elevar), docetaxel micellar and Cantrixil.
-
Francois R. Martelet, Chief Executive Officer, Oasmia
Francois Martelet is an experienced Pharmaceutical and Biotechnology executive with a proven track record of shaping companies and turning around underperforming units. He has held three CEO positions in the last 12 years. He has spent most of his career in the oncology field, as CEO of Avax and Topotarget, as well as in executive corporate roles at senior level at Roche, Eli Lilly, Novartis and MSD. Throughout his various assignments he has been based in six countries in Europe (including Sweden) and in the US. Francois is a Medical Doctor, with a Masters Degree in Business from France. He is also a military reserve officer holding the rank of Brigadier (OF-6) and has received the Legion of Honor on military grounds that is the highest decoration in France.
